CTSC and COVID-19: More intriguingly, a phase III clinical trial “STOP-COVID19” is running to evaluate whether the CTSC (DPP1) inhibitor Brensocatib (DB15638) could help COVID-19 patients (https://stop-covid19.org.uk/).